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Abstract 
Irinotecan is used clinically for the treatment of colorectal cancer; however, its utility is limited by its 
narrow therapeutic index. We describe the use of a generation 5 L-lysine dendrimer that has been 
part-modified with a polyoxazoline as a drug delivery vehicle for improving the therapeutic index of 
SN-38, the active metabolite of irinotecan. By conjugating SN-38 to the dendrimer via different linker 
technologies we sought to vary the release rate of the drug to generate diverse pharmacokinetic 
profiles. Three conjugates with plasma release half-lives of 2.5 h, 21 h, and 72 h were tested for 
efficacy and toxicity using a mouse SW620 xenograft model. In this model, the linker with a plasma 
release half-life of 21 h achieved sustained SN-38 exposure in blood, above the target concentration. 
Control over the release rate of the drug from the linker, combined with prolonged circulation of the 
dendrimer, enabled administration of an efficacious dose of SN-38, achieving significant regression 
of the SW620 tumours. The conjugates with 2.5 and 72 h release half-lives did not achieve an anti-
tumour effect. Intraperitoneal dosing of the clinically used prodrug irinotecan produces high initial 
and local concentrations of SN-38, which are associated with gastrointestinal toxicity. Administration 
of the 21 h release dendrimer conjugate did not produce a high initial Cmax of SN-38. Consequently, a 
marked reduction in gastrointestinal toxicity was observed relative to irinotecan treatment. 
Additional studies investigating the dose concentrations and dose scheduling showed that a weekly 
dosing schedule of 4 mg SN-38/kg was the most efficacious regimen. After 4 doses at weekly 
intervals, the survival period of the mice extended beyond 70 days following the final dose. These 
extensive studies have allowed us to identify a linker, dose and dosing regimen for SN-38 conjugated 
to polyoxazoline-modified dendrimer that maximised efficacy and minimised adverse side effects.  
 
t1/2 = 2.5 h “Fast”
t1/2 = 21 h “Medium”
t1/2 = 72 h “Slow”
SN-38
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1. Introduction 
One of the key considerations for cancer medicines remains establishing a therapeutic index [1], 
since targeting key cellular processes can induce significant toxicity, and therapeutic margins are 
typically narrow, or almost non-existent for some specific potent cytotoxic therapies.  
 
Topoisomerases are ubiquitous enzymes that control DNA supercoiling and entanglements. They 
cleave the DNA backbone, releasing DNA supercoils and re-ligating the cleaved DNA. 
Topoisomerases are essential during the transcription and replication process, and topoisomerase 
inhibitors that cause single or double strand cleavage (type I or II, respectively) are among the most 
effective and most commonly used anticancer and antibacterial drugs [2]. Topotecan and irinotecan 
are topoisomerase I inhibitors routinely used in the clinic in a range of different cancers. They are 
water soluble semi-synthetic derivatives of the potent cytotoxic plant alkaloid camptothecin. 
However, serious adverse effects, including myelosuppression and diarrhoea, have limited their 
efficacy in the clinic. 
 
In addition, irinotecan is a prodrug, which is hydrolysed to its more potent active metabolite, SN-38, 
by carboxylesterases in the liver and tumour cells. This conversion is often inefficient in humans, and 
leads to variability in SN-38 exposure [3]. Although SN-38 is ~100- to 1000-fold more potent than 
irinotecan [3], its clinical use is limited by its poor water solubility and chemical instability of its 
pharmacologically active lactone ring at pH >6. Alongside the narrow therapeutic index of irinotecan 
and SN-38, these issues present further challenges for their use as anti-cancer therapeutics in the 
clinic.   
 
In principle, one way to improve therapeutic index is to increase drug exposure in diseased tissue, 
without accumulation in other healthy tissues. Nanotechnology offers the possibility to achieve 
greater site specificity by changing the biodistribution of a drug. These drug delivery systems have 
been shown to increase drug concentration at tumour sites, relative to off-target tissues. This is 
often achieved by minimising the high initial drug concentrations in the plasma (Cmax) and allowing 
tissue accumulation and retention via the enhanced permeability and retention (EPR) effect [4, 5]. 
The rapidly developing field of nanomedicines covers a range of nano-scale constructs, such as 
liposomes, polymeric nanoparticles, polymeric micelles, various polymer conjugates and inorganic 
particles. 
 
Several nanomedicine delivery strategies have been investigated to improve the therapeutic index of 
SN-38 and camptothecin analogues, by reducing accumulation in normal tissues while increasing 
delivery to tumours. To date, SN-38 and camptothecin analogues have been delivered using 
liposomes, polymeric nanoparticles, polymeric micelles and various polymer conjugates and 
antibody drug conjugates [6-12].  
 
Onivyde™ (Merrimack Pharmaceuticals), a liposomal irinotecan, has recently been approved for use 
in metastatic pancreatic cancer and is currently being used in Phase II trials in gastric cancer. 
Etirinotecan pegol (ONZEALD™, formerly NKTR-102; Nektar Therapeutics) is in advanced clinical 
development for ovarian, breast, colon, and lung cancers [13, 14]. Both of these nano-formulations 
provide greater area under the curve (AUC) for SN-38 than does irinotecan treatment in pre-clinical 
tumours [14]. A camptothecin nanoparticle polymer conjugate, CRLX101 (Cerulean Pharma Inc.) is 
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currently in clinical trials in a number of cancers. CRLX101 has demonstrated an extended circulation 
half-life and prolonged release of camptothecin in rat, dog, and human plasma [15], sustained 
tumour pharmacokinetics and inhibition of target [16], and evidence of localisation in tumour rather 
than healthy tissues in gastric cancer patients [17].  
 
All of these systems have demonstrated positive results in pre-clinical models and are progressing in 
the clinic with promising activity. However, the ability to control the release of the payload from the 
nano-carrier has not been explored, precluding the possibility of fine-tuning the release rate to 
maximise the therapeutic index. The ability to explore the relationship between efficacy and toxicity 
across a range of release rates generates insight that drives biology-focussed nanomedicine design 
[18].  
 
Dendrimer drug conjugates offer many advantages over other drug delivery systems, including 
tuneable drug release. Additional benefits of the dendrimer platform include: control of size during 
synthesis, near-monomodal molecular weight distributions, and reproducible synthetic sequences. 
Dendrimers are significantly smaller (~7-15 nm) than polymeric nanoparticles prepared via other 
routes. Nanomedicine systems of similar sizes have been shown to extravasate to a greater extent 
and/or penetrate farther from the vasculature than do larger systems, which has been associated 
with improved efficacy [19-21]. In addition, dendrimers have large numbers of surface groups 
available for conjugation. These surface groups can be used for drug conjugation via different linker 
chemistries, without significantly impacting solubility, or to modify the outer layer of the dendrimer. 
This modification controls surface charge and provides a corona to prevent protein adsorption, 
thereby extending the circulation time of the dendrimer conjugate. PEGylation has been widely 
employed with polyamidoamine (PAMAM) [22-25] and poly(L-lysine) dendrimers [26-29] for surface 
modification. There is now significant diversity in the dendrimer-based nanomedicines being 
explored pre-clinically, including amphiphilic dendrimers forming nanomicelles [30], dendrimer-
assisted metal nanocomposite particles for CT/MR imaging [31], lactoferrin-containing dendriplexes 
[32], and doxorubicin-conjugated dendrimers for pulmonary delivery [33].  
 
We have built on this strategy using a biodegradable fifth generation L-lysine dendrimer, part-
modified with a polyoxazoline [34], to deliver the potent topoisomerase I inhibitor SN-38.  
Recognising the importance of controlled drug release in designing nanomedicines and optimising 
therapeutic index [35-40], we designed a range of linker chemistries to tune the release rate of SN-
38, and explored the synthesis, characterisation and therapeutic application of three dendrimer-
SN38 (Dend-SN38) conjugates in vitro and in vivo. 
 
 
2. Materials and methods 
Materials 
All reagents and solvents were purchased from Sigma-Aldrich and used as received with exception of 
SN-38 (TCI Europe N.V.), N,N′-Disuccinimidyl carbonate & 2-chloro-4,6-dimethoxy-1,3,5-triazine 
(Chem-Impex International). Irinotecan was purchased from CarboSynth (UK). 
 
Methods 
HPLC-UV was performed on an Agilent 1100 fitted with an Atlantis dC18 5 μm 4.6 x 150 mm column 
with an acetonitrile/water gradient + 1% TFA modifier. See Supporting Information Table S1 for 
HPLC-UV run parameters. The data were analysed using Thermo Scientific™ Atlas Chromatography 
Data System (CDS) software. GPC was performed on a Malvern TDA302 using a Tosoh Bioscience 
TSKgel GMPWxl column and an eluent of a 40: 10 mM NaNO3: NaH2PO4 + 10% MeOH in water. 
Samples were made to 2 mg/ml in the eluent. The system calibration was performed using a single 
poly(ethylene oxide) standard (16 100 g mol−1) and absolute molecular weights determined using the 
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refractive index and light scattering signals. Dynamic light scattering was performed on a Malvern 
Zetasizer® Nano ZS instrument with back scattering detector (173°, 633 nm laser wavelength). The 
dispersant RI and viscosity were assumed to be that of water (n = 1.59 and η = 0.888 mPa·s). The 
sample RI was 1.59 and the temperature was set at 25°C. The hydrodynamic diameter (DH) was 
reported as the volume-weighted average after a minimum of twelve measurements per sample and 
was calculated by the software. Samples were made to concentrations of 5 mg/ml in PBS at pH 7.4 
and were filtered using a 0.2 μm syringe filter prior to measurement. Data was obtained using 
Malvern Zetasizer software version 6.21J. 
 
4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium tetrafluoroborate (DMTMM.BF4) was 
synthesised according to methods reported previously [41]. 
 
G5-PLL[PMOx]x[NH2]y. This product was synthesised according to methods previously described [34]. 
Mn = 75.7 kg/mol, PDI = 1.17 from triple detection size exclusion chromatography. 
 
G5-PLL[PMOx]x[Azide]y. G5-PLL[PMOx][NH2] (750 mg, 9.78 μmol) was dissolved in anhydrous DMF (5 
mL) at 45°C. The solution was cooled to room temperature. A pre-mixed solution of 2-azidoacetic 
acid (93 μL, 1.25 mmol), N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) (240 
mg, 1.25 mmol) and 4-(Dimethylamino)pyridine (DMAP) (15 mg, 0.12 mmol) in anhydrous DMF (5 
mL) was added to the polymer solution and stirred overnight at room temperature. The reaction 
mixture was added drop-wise to rapidly stirring diethyl ether (200 mL) to form a white precipitate 
which was collected by filtration and dried under vacuum for 2 hours at room temperature. The solid 
was then taken up in deionised water (50 mL), passed through a 0.45 μm nylon filter cup and 
purified by VivaFlow® cassette in deionised water (30 kDa MWCO). The title compound was 
obtained as a white solid after freeze-drying (675 mg, 87 %). 1H NMR (400 MHz, D2O) 1.12 – 1.86 (br, 
367H), 1.89 – 2.3 (br, 1500H), 3.19 (br, 136H), 3.56 (br, 1940H), 3.92 (br, 111H), 4.04 – 4.44 (br, 
130H). 
 
6-amino-N-(prop-2-ynyl)hexanamide. Boc-6-aminohexanoic acid (1.0 g, 4.32 mmol) was dissolved in 
anhydrous DCM (25 mL) in a reaction tube purged with nitrogen. EDC (1.34 g, 8.64 mmol) was added 
as a solid and stirred until dissolved. DMAP (0.1 g, 8.65 mmol) was added followed by 
propargylamine (0.831 mL, 12.97 mmol) dropwise via Gilson pipette. The reaction was stirred 
overnight at room temperature before diluting with further DCM (25 mL) and washing with 0.1M HCl 
(2 x 25 mL), saturated NaHCO3 (2 x 25 mL) and saturated brine (25 mL). The organic phase was dried 
over magnesium sulphate, filtered and evaporated under vacuum to obtain the title compound as a 
white solid (0.632 g, 55 %).1H NMR (CDCl3, 400 MHz): δ=1.36 (m, 2H), δ=1.44 (s, 9H), δ=1.50 (m, 
2H), δ=1.67 (m, 2H), δ=3.11 (q, 2H), δ=4.05 (dd, 2H), δ=4.46-4.61 (b, 1H), δ=5.56-5.69 (b, 1H). 
 
6-amino-N-(prop-2-yn-1-yl)hexanamide.HCl. 6-amino-N-(prop-2-ynyl)hexanamide (0.60 g, 2.24 
mmol) was dissolved in methanol (5 mL) in a round bottom flask fitted with a gas outlet. HCl (1.68 
mL, 4M in dioxane) was added drop-wise and the reaction was stirred at room temperature for 6 
hours. The solvents were evaporated under vacuum and the residue was washed with DCM (25 mL). 
The remaining solid was dried under vacuum at room temperature overnight to give the title 
compound as a pale brown solid (0.39 g, 85 %). 1H NMR (400MHz, d-DMSO) 1.22 – 1.37 (2H, m), 
1.49 (2H, m), 1.53 – 1.62 (2H, m), 2.09 (2H, t), 2.64 – 2.82 (2H, m), 3.06 (1H, t), 3.83 (2H, dd). 
 
tert-butyl methyl(3-oxo-3-(prop-2-yn-1-ylamino)propyl)carbamate. This compound was 
synthesized as above using boc-sarcosine (1.0 g, 5.29 mmol). The title compound was obtained as a 
white solid (0.59 g, 49 %). 1H NMR (CDCl3, 400 MHz): δ=1.48 (s, 9H), δ=2.23 (t, 1H), δ=1.48 (s, 3H), 
δ=3.86 (s, 2H), δ=4.07 (dd, 2H).  
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2-(methylamino)-N-(prop-2-ynyl)acetamide.HCl. This compound was synthesised according to the 
above method. The title compound was obtained as a pale brown solid (0.38 g, 72 %). 1H NMR (d6-
acetone, 400 MHz): δ=2.87 (s, 3H), δ=3.66 (s, 1H), δ=3.98 (m, 4H). 
 
SN-38 6-oxo-6-(prop-2-ynylamino)hexylcarbamate (1a). SN-38 (75 mg, 0.19 mmol) was dissolved in 
a mixture of THF (6 mL) and acetonitrile (6 mL) with N,N-Diisopropylethylamine (DIPEA) (0.100 mL, 
0.57 mmol) in a 10 mL reaction vial purged with nitrogen. bis(2,5-dioxopyrrolidin-1-yl) carbonate 
(196 mg, 0.76 mmol) was added directly as a solid. The reaction was monitored by HPLC and when 
full conversion of the SN-38 was observed (~30 min) the reaction mixture was diluted with EtOAc (25 
mL), and washed with 0.1M HCl (2 x 10 mL) and saturated brine (2 x 10 mL). The organic layer was 
dried over MgSO4, filtered and evaporated to afford the intermediate. The intermediate was 
dissolved in DCM (15 mL) before DMAP (9.34 mg, 0.08 mmol), and 6-Amino-N-(prop-2-yn-1-
yl)hexanamide.HCl (58.7 mg, 0.29 mmol) dissolved in DMF (2 mL) were added followed by DIPEA (33 
μL, 0.19 mmol). The reaction mixture was stirred at room temperature under nitrogen until the 
reaction had gone to completion (measured by LCMS, ~10 min). The solvent was evaporated and the 
crude product was purified by flash silica chromatography with an elution gradient of 10-80% 3:1 
EtOAc: EtOH in heptane. The title compound was obtained as a pale yellow solid after evaporation. 
(85 mg, 76 %). 1H NMR (400 MHz, CDCl3) 1.04 (4H, t), 1.31 – 1.49 (8H, m), 1.6 – 1.69 (3H, m), 1.72 
(3H, dd), 1.79 – 2 (3H, m), 2.15 – 2.29 (4H, m), 2.51 – 2.63 (1H, m), 2.74 (2H, s), 2.88 (2H, d), 2.95 
(2H, s), 3.16 (2H, q), 3.34 (2H, dt), 4.06 (3H, dd), 5.26 (3H, s), 5.28 – 5.37 (2H, m), 5.75 (1H, d), 7.60 
(1H, dd), 7.63 (1H, s), 7.88 (1H, d), 8.21 (1H, d). 
 
SN-38 methyl(2-oxo-2-(prop-2-ynylamino)ethyl)carbamate (1c). This compound was synthesized as 
for 1a using 1a using 2-(methylamino)-N-(prop-2-ynyl)acetamide.HCl. The title compound was 
obtained as a pale yellow solid (76 mg, 73 %). 1H NMR (400 MHz, CDCl3) 1.04 (3H, t), 1.42 (3H, dt), 
1.54 (3H, s), 1.75 – 2 (2H, m), 2.26 (1H, s), 3.15 (3H, d), 3.30 (2H, s), 3.49 (1H, s), 3.76 (1H, d), 3.96 – 
4.28 (4H, m), 5.24 (2H, s), 5.27 – 5.33 (1H, m), 5.75 (1H, dd), 7.61 (2H, s), 7.8 – 7.92 (1H, d), 8.22 (1H, 
d). 
 
SN-38 hex-5-ynoate (1b). Hex-5-ynoic acid (23 μL, 0.21 mmol) was dissolved in anhydrous DMF (7 
mL) in a nitrogen-purged reaction vial. EDC (73.3 mg, 0.38 mmol) was added as a solid, followed by 
DMAP (46.7 mg, 0.38 mmol) and the mixture stirred for 5 minutes. 7-Ethyl-10-hydroxycamptothecin 
(75 mg, 0.19 mmol) was added as a solid and the reaction stirred overnight. The reaction mixture 
was diluted with ethyl acetate (50 mL), and washed with 0.1M HCl (2 x 20 mL), and saturated brine 
(2 x 20 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford the crude 
product. The crude was purified by flash silica chromatography with a 20-70% elution gradient of 3:1 
EtOAc: EtOH in heptane. The title compound was obtained as a pale yellow solid after evaporation of 
the solvents (69.2 mg, 74.4 %). 1H NMR (400 MHz, CDCl3) 1.04 (3H, t), 1.40 (3H, t), 1.90 (2H, ddt), 
1.99 – 2.11 (3H, m), 2.41 (2H, td), 2.83 (2H, t), 3.15 (2H, q), 5.25 (2H, s), 5.27 – 5.33 (1H, m), 5.74 (1H, 
d), 7.55 (1H, dd), 7.64 (1H, s), 7.83 (1H, d), 8.23 (1H, d). 
 
2-(4-(4-oxo-4-SN38 butyl)-1H-1,2,3-triazol-1-yl)acetic acid (1b’). The reaction for 1b was repeated 
starting with 300mg of SN-38 to yield 294mg (0.60 mmol) of product (79.0%). This product was 
dissolved in anhydrous DMF (10 mL) in a nitrogen purged reaction vial. 2-azidoacetic acid (227 μL, 
3.02 mmol) was added via Gilson pipette followed by copper(II) sulphate pentahydrate (15 mg, 0.06 
mmol) and sodium ascorbate (24 mg, 0.12 mmol). After 10 minutes the reaction had gone to 
completion as observed by LCMS and the reaction mixture was diluted with ethyl acetate (100 mL) 
and was washed with 0.1M HCl (3 x 25 mL) and saturated brine (3 x 25 mL). The organic phase was 
dried over magnesium sulphate and dried under vacuum. The crude was purified by flash silica 
chromatography with an elution gradient of 10-80% 3:1 EtOAc: EtOH + 10% AcOH in heptane. The 
title compound was obtained as a pale yellow solid after evaporation of the solvents (278 mg, 78 %). 
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1H NMR (400 MHz, d-DMSO) 0.90 (3H, q), 1.31 (3H, t), 1.89 (2H, tq), 2.06 (2H, p), 2.71 – 2.85 (4H, m), 
3.20 (3H, q), 5.19 (2H, s), 5.35 (2H, s), 5.44 (2H, s), 6.48 (1H, s), 7.34 (1H, s), 7.68 (1H, dd), 7.92 (1H, 
s), 8.03 (1H, d), 8.22 (1H, d). 
 
G5-PLL[PMOx]x[1a]y   (2a).  G5-PLL[PMOx]x[Azide]y (150 mg, 1.89 µmol) was dissolved in water (2 mL) 
in a nitrogen purged reaction vial. 1a (44 mg, 0.08 mmol) dissolved in methanol (6 ml) was added 
followed by copper(II) sulphate pentahydrate (2.4 mg, 9.45 µmol) and sodium ascorbate (3.7 mg, 
0.02 mmol). The reaction mixture was stirred for 1 hour before reducing the volume of the reaction 
mixture by half under vacuum. The product was purified by size exclusion column (LH20) in 
methanol, collecting 0.5 mL fractions which were evaporated, taken up in deionised water and 
freeze-dried. The polymer fractions were collated to give the title compound as a pale yellow solid 
(184 mg, 96 %). D.L. = 8.1 wt. %.  1H NMR (400 MHz, D2O) 1.12 – 1.86 (br, 367H), 1.89 – 2.3 (br, 
1500H), 3.19 (br, 136H), 3.56 (br, 1940H), 3.92 (br, 111H), 4.04 – 4.44 (br, 130H), 6.92-8.04 (br, 98H, 
SN-38). 
 
G5-PLL[PMOx]x[1b]y  (2b). This product was synthesised as for 2a to yield a pale yellow solid (125 
mg, 69 %). D.L. = 8.5 wt.%.  1H NMR (400 MHz, D2O) 1.12 – 1.86 (br, 367H), 1.89 – 2.3 (br, 1500H), 
3.19 (br, 136H), 3.56 (br, 1940H), 3.92 (br, 111H), 4.04 – 4.44 (br, 130H), 6.92-8.04 (br, 101H, SN-38). 
 
G5-PLL[PMOx]x[1c]y  (2c). This product was synthesised as for 2a to yield a pale yellow solid (133 mg, 
73 %). D.L. = 8.3 wt. %.  1H NMR (400 MHz, D2O) 1.12 – 1.86 (br, 367H), 1.89 – 2.3 (br, 1500H), 3.19 
(br, 136H), 3.56 (br, 1940H), 3.92 (br, 111H), 4.04 – 4.44 (br, 130H), 6.92-8.04 (br, 103H, SN-38). 
 
G5-PLL[PMOx]x[1b’]y. (2b’) Product 1b’ (250 mg, 0.43 mmol) was dissolved in anhydrous DMF 
(10mL) and DMTMM.BF4 (225mg, 0.69mmol) was added. The reaction mixture was stirred for 10 
minutes at room temperature. G5-PLL[PMOx]x[NH2]y (820 mg, 10.71 µmol) and triethylamine (48μL, 
0.34mmol) dissolved in anhydrous DMF (5 mL) were added and the reaction mixture stirred under 
nitrogen at room temperature for 5 hours (the reaction progress was regularly followed by LC-MS at 
254 nm). The reaction mixture was diluted with ethyl acetate (15 mL) and then added dropwise to 
rapidly stirring diethyl ether (500 mL) to form a pale yellow precipitate. The precipitate was collected 
and dried under vacuum at room temperature for 1 hour. The solid was taken up in 50 mL of a 2:1:1 
mixture of 0.1M KH2PO4 buffer (pH3), DI water and ethanol before purifying by VivaFlow (30 kDa 
MWCO) for several cycles, before changing over to 100% deionised water when the solution was 
absent of impurities and free drug as detected by LC-MS. The title compound was obtained as a pale 
yellow solid after freeze-drying (850 mg, 84 %). D.L. = 7.7 wt. %.  1H NMR (400 MHz, D2O) 1.12 – 1.86 
(br, 367H), 1.89 – 2.3 (br, 1500H), 3.19 (br, 136H), 3.56 (br, 1940H), 3.92 (br, 111H), 4.04 – 4.44 (br, 
130H), 6.92-8.04 (br, 94H, SN-38). 
 
Compound formulation 
For i.p. dosing, irinotecan was formulated in 7.5% DMSO + 92.5% water for injection (v/v); for i.v. 
dosing, irinotecan was formulated in 2.5% DMSO + 97.5% water for injection (v/v) and sterile-
filtered. SN-38 was dissolved in saline according to the following method: SN-38 was dissolved in 
NaOH solution (2M) (3.5 μL per 1 mg SN-38). The bright yellow solution was diluted with the 
required volume of saline and then HCl (2M) (1 μL for every 1 mg of SN-38 used) was added to 
ensure a stable, near-neutral solution was achieved. Dend-SN38 and unloaded dendrimer were 
hydrated in saline and sterile-filtered before injection. 
 
Dend-SN38 free drug loading 
An accurately weighed quantity of Dend-SN38 (1-2 mg) was weighed directly into a HPLC vial and 
dissolved in 1 mL of a 2:1 Methanol: KH2PO4 (0.1 M) mixture. The samples were measured by HPLC-
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UV immediately after dissolution (to minimise any release of SN-38) and the free drug content was 
reported as a weight percentage from an average of 2 runs per sample.  
 
Dend-SN38 total drug loading  
Full release of SN-38 from the dendrimer was achieved by dissolving an accurate quantity of Dend-
SN38 (1-2 mg) in sodium hydroxide solution (0.2 M, 1 mL) in a sealed HPLC vial and leaving at room 
temperature overnight (whilst prior hydrolysis studies having shown full release under these 
conditions in approximately 2 h (data not shown)). The drug loading was measured by HPLC-UV (254 
nm), 1% ammonia in place of TFA) against a 6 point calibration curve for the ring-open (carboxylate) 
form of SN-38 dissolved in sodium hydroxide solution (0.2 M). The total drug loading was reported 
as a weight percentage from an average of 2 runs per sample. 
 
Dend-SN38 in vitro release rates  
Dend-SN38 conjugates (2a-c) were weighed into HPLC vials (2 vials of 1.5 mg per sample) and Wistar 
rat plasma (500 μL) was added and gently mixed briefly until the conjugates had dissolved. Rat 
plasma was utilised to ensure that a sufficient volume for all experiments could be obtained in a 
single batch to eliminate batch-to-batch variation. The vials were sealed and incubated at 37°C. 25 
μL aliquots were taken at time points 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 8 h, 24 h, 48 h, 72 h and 96 h. The 
samples were added directly to a Mini-UniPrep filter vial together with 300 μL 10% AcOH in ACN. 
The sample was agitated for 2 minutes before filtering. 200μL of the filtered solution was added to a 
separate HPLC vial with 300 μL of a 2:1 methanol: KH2PO4 (0.1 M) mixture and agitated before 
immediately measuring the released SN-38 content by HPLC-UV (265 nm). Full release of the SN-38 
was measured by removing 25 μL of the incubated plasma and adding 5μL of 2 M NaOH and then 
incubating at 37°C overnight in a sealed 96-well plate. The plate was cooled over an ice bath and 
then the samples were neutralised by addition of 5 μL of 2 M HCl and repeating the same steps as 
above accounting for the difference in volume when calculating the released SN-38. Release 
measurements in PBS were made similarly, except that 25 μL aliquots were added directly to a HPLC 
vial with 300 μL of a 2:1 methanol: KH2PO4 (0.1 M) mixture and measured directly by HPLC-UV.  
 
Animal models 
All animal studies were conducted in accordance with UK Home Office legislation, the Animal 
Scientific Procedures Act 1986, and the AstraZeneca Global Bioethics policy. All experimental work is 
outlined in project license 40/3483, which has gone through the AstraZeneca Ethical Review Process. 
Female nude (Hsd: Athymic Nude-Foxn1 nu) mice were purchased from Harlan Laboratories (now 
Envigo; UK). All mice weighed more than 18 g at the time of the first procedure. For studies in 
SW620 tumour-bearing mice, 1 x 106 cells in 50% Matrigel were implanted subcutaneously onto the 
left flank of mice. Tumour growth was monitored twice weekly using intersecting calliper 
measurements; tumour volume was calculated from 3.14*length*width2/6000, where length is the 
longer dimension. Bodyweights were recorded at the time of tumour measurement, and daily if 
weight loss exceeded 8%. Mice were randomised based on tumour volume to ensure an equal 
volume distribution across groups. 
 
Dend-SN38 pharmacokinetics 
To determine the plasma SN-38 concentrations achieved by the Dend-SN38 conjugates with 
different release rates, naive female nude mice (n = 2/group) were injected intravenously with a 
single dose of slow, medium or fast release Dend-SN38 at 4 mg/kg. Live bleeds were collected at 
various time points post-dose for determination of concentrations of free and bound SN-38 via 
UPLC-MS/MS (conditions in Supporting Information Tables S2 and S3) against an SN-38 calibration 
curve (11 point standard calibration curve (1-10000 nM) prepared in DMSO and spiked into blank 
plasma). Briefly, 20 µL of blood was collected from the tail vein using capillary tubes. Blood was 
diluted with 80 µL of PBS and centrifuged at 13,000 rpm for 5 min at 4°C. The supernatant was 
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collected and stored at -80°C until analysis. At the time of analysis, the samples were defrosted over 
ice and two separate aliquots of 30 μL were taken from each sample for liberated and total SN-38 
concentrations. For liberated SN-38, 120 μL of methanol/acetonitrile (50/50) + 1% acetic acid was 
added to the first aliquot to precipitate protein and stabilise any residual dendrimer-bound SN-38. 
The precipitate was agitated for 45 seconds before being filtered using a Mini-UniPrep Syringeless 
Filter (0.45 μm). 50 μL of the filtrate was transferred to a deep 96-well plate and diluted with 
deionised water (300 μL) and frozen at -80°C prior to analysis. For the second aliquot where total SN-
38 levels were desired, the sample was placed into a 96-well plate and 5 μL of sodium hydroxide (2 
M) was added. The plate was sealed with adhesive 96-well sealing tape and incubated at 40°C for 2 
hours and was then placed on to an ice bath for 5 minutes before removing the sealing tape. 5 μL of 
HCl (2 M) was added and the well contents were transferred to a Mini-UniPrep Syringeless Filter 
(0.45 μm) followed by 110 μL of acetonitrile/methanol (50/50) + 1% acetic acid and the same 
procedure for filtration of protein and transfer to deep 96-well plate was followed as for the 
liberated levels of SN-38. Whilst some of the intact dendrimer was removed by the acetonitrile 
protein precipitation, additional steps to prevent post-workup release form any intact dendrimer 
was minimised by addition of KH2PO4 buffer. Samples were measured immediately after workup or 
frozen at -80oC until measurements could be made. 
 
SN-38 pharmacokinetics 
To characterise the plasma pharmacokinetics of SN-38 (carboxylate form), SW620 tumour-bearing 
mice (n = 5) were injected intravenously with a single dose of SN-38 at 2 mg/kg. Live bleeds were 
collected at various time points post-dose for determination of SN-38 concentrations via UPLC-
MS/MS. The same procedure for sample preparation was used as for the Dend-SN38 
pharmacokinetics above. 
 
Analysis of SN-38 concentration in tumours 
Tumours were weighed and put into FastPrep Lysing Matrix A Tubes (MP Biomedicals UK). Three 
times the volume of water per tumour weight was added to the tumour for homogenisation. The 
samples were homogenised using a FastPrep-24™ machine (MP Biomedicals UK) at 6 m/s for 45 
seconds. The cycle was repeated twice to gain complete homogenisation. Control tissue from 
undosed animals was homogenised as above and spiked with an 11 point standard calibration curve 
(1-10000 nM SN-38) prepared in DMSO. Tissue homogenates (25 µL) were precipitated with 
acetonitrile (100 µl) containing internal standard, followed by centrifugation at 4500 rpm for 10 
minutes. The supernatant (50 µl) was then diluted in 300 µl water and analysed via UPLC-MS/MS.  
 
Effect of Dend-SN38 release rate on anti-tumour efficacy 
To investigate the effect of Dend-SN38 release rate on anti-tumour activity and therapeutic index, an 
efficacy study was completed in mice bearing SW620 tumours. Animals were randomised for dosing 
when the average tumour volume reached ~0.2 cm3. Mice (n = 8-10 mice/group) were dosed once 
weekly with saline (i.v.), irinotecan at 25 mg/kg (i.v.), irinotecan at 50 mg/kg (i.p.), unloaded 
dendrimer at 50 mg polymer/kg (i.v.), or slow, medium or fast release Dend-SN38 conjugates at 4 
mg SN-38/kg (i.v.). A dose of 4 mg SN-38/kg required administration of 50 mg Dend-SN38/kg, 
equalling ~8% drug loading. Unless specified otherwise, the reported dose for the dendrimer 
conjugates is the dose of SN-38, not the polymer dose. Mice treated with irinotecan or medium 
release Dend-SN38 received 4 doses, while all other groups received 3 doses before tumour burden 
necessitated euthanasia as defined in the Project Licence. At 24 h after the final dose, mice were 
euthanised and the gastrointestinal tract (n = 5/group) was excised, fixed in formalin, and embedded 
in paraffin for assessment of changes to the gastrointestinal tract suggestive of drug toxicity. 
Statistical significance was determined versus Control at day 16 post-dose using a one-sided two-
sample unequal variance t-test. 
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Effect of Dend-SN38 dose and schedule on anti-tumour efficacy  
To explore how the dose and schedule of the medium release Dend-SN38 conjugate influenced the 
therapeutic activity, an efficacy study was completed in mice bearing SW620 tumours. Animals were 
randomised for dosing when the average tumour volume reached ~0.2 cm3. Mice were dosed (n = 
9/group) once weekly for 4 cycles with saline (i.v.), irinotecan at 50 mg/kg (i.p.), or medium release 
Dend-SN38 at 2, 4, or 8 mg/kg (i.v.). At 24 h after the 4th dose, 3 mice per group were euthanised to 
assess GI toxicity. The remaining mice were kept on study to evaluate tumour re-growth after the 
final dose. The effect of dose scheduling was also investigated by administering the medium release 
Dend-SN38 every 2 weeks for 2 cycles at 4 or 8 mg/kg (i.v.). Statistical significance was determined 
versus Control at day 23 post-dose using a one-sided two-sample unequal variance t-test. 
 
Tumour pharmacodynamic effect of irinotecan and Dend-SN38  
An acute dosing study was completed in SW620 tumour-bearing mice to compare the time course of 
tumour DNA damage. To ensure sufficient tumour material was available for analysis, animals were 
randomised for dosing when the average tumour volume reached ~0.5 cm3. Mice (n = 3-4/group) 
were treated with a single dose of irinotecan at 50 mg/kg (i.p.) or medium release Dend-SN38 at 4 
mg/kg (i.v.). At 24 h, 72 h, or 120 h post-dose, mice were euthanised and the tumour was excised 
and fixed in formalin and embedded in paraffin.  
 
Assessment of gastrointestinal toxicity 
To compare the severity of gastrointestinal toxicity caused by treatment with irinotecan and the 
Dend-SN38 conjugates, haematoxylin and eosin (H&E)-stained sections (4-6 µm) of formalin-fixed 
paraffin-embedded (FFPE) duodenum, jejunum, ileum, and colon were examined by a trained 
pathologist. Each segment was assessed and the severity of histopathological changes (crypt 
degeneration and atrophy) was graded using a semi-quantitative (0-5) scoring system (0, none; 1, 
minimal; 2, mild; 3, moderate; 4, marked; 5, severe).  
 
Assessment of DNA damage in tumours 
Immunohistochemical staining for ɣH2A.X was completed to assess DNA damage in tumours. FFPE 
tumour sections (4 µm) were dewaxed with xylene and rehydrated through graded ethanols to 
water. Antigen retrieval was performed in pH 9 buffer at 110°C for 2 min in a RHS histoprocessor 
microwave. Endogenous enzyme activity was blocked with 3% hydrogen peroxide. Slides were 
incubated with serum free protein block (Dako) for 20 min before the primary antibody (anti-
phospho-histone H2A.X (Ser139); 1:300; Cell Signalling Technology) was added for 1 h at room 
temperature. The Dako Envision+ (anti-rabbit) peroxidase-labelled polymer system was applied for 
30 min, and slides were then incubated with 3,3’-diaminobenzidine (DAB; Dako) for 10 min. Slides 
were counterstained with Carazzi’s haematoxylin, dehydrated through graded ethanols to xylene, 
and coverslipped. Positive staining was measured using an in-house analysis developed using 
ImageScope (v11.2.0.780; Aperio). Statistical significance between treatments was determined using 
one-way ANOVA with Sidak’s multiple comparisons post-test. 
 
Detection/localisation of SN-38 in tumour using Desorption Electrospray Ionization – Mass 
Spectrometry Imaging (DESI-MSI) 
Snap-frozen tumour tissues were cryo-sectioned using a Leica CM3050 S (Leica Microsystems) 
cryostat to a thickness of 14 µm, thaw mounted onto Superfrost microscope slides and stored at -
80°C until analysis. DESI imaging experiments were performed on a Thermo Scientific Q-Exactive 
instrument (Bremen, Germany) equipped with a 2D automated DESI source from Prosolia Inc. 
(Indianapolis, IN, USA) using a home-built sprayer assembly as described previously [42]. Detection 
of SN-38 was performed in negative ion mode as [M-H]-, while Irinotecan was detected in positive 
ion mode as [M+H]+. To allow detection of both compounds in a single imaging experiment, 
negative and positive ion mode were alternated during analysis. Analysis was performed at R = 
10 
 
70,000 mass resolving power and 50 V S-Lens Voltage. Methanol/water (95: 5 v/v) was used as 
electrospray solvent at 4.5 kV spray voltage and a flow rate of 1.5 µL/min. Solvent was delivered 
using a Dionex Ultimate 3000 stand-alone nanoLC pump (Thermo Scientific). Nitrogen N4.8 was used 
as nebulising gas at a pressure of 7 bar. Distance between sprayer to sample surface was 1.5 mm 
while distance between sprayer and MS inlet was 7 mm. The spray angle was set to 75° while 
collection angle was set at 10°. The capillary temperature was set to 320°C. Data was converted into 
centroid .imzML format using imzML converter version 1.1.4.5 [43] and visualised using MSiReader 
v0.05 [44]. All intensities shown are raw ion intensities. 1st order linear interpolation was used for 
image generation. Samples were stained with H&E post-DESI analysis and digitalised using a Leica 
Aperio AT2 slide scanner (Leica Microsystems).  
 
Measurements to determine the sensitivity of the DESI-MSI technique 
SN-38 and irinotecan standard solutions dissolved in 50% MeOH (diluted from a stock solution in 
DMSO) were spotted onto six adjacent tumour tissue sections. 1 μL of standard solutions with 
concentrations ranging from 50 uM to 0.1 uM was spotted taking care to ensure that the standards 
were spotted onto comparable positions of the tissue sections. Tissue sections were subsequently 
analysed by DESI-MSI using the experimental parameters as described for the SN-38 localisation.  
To calculate on-tissue concentrations, the assumption was made that standard solutions had 
distributed evenly throughout the tissue volume under the calibration spot. Tissue thickness was 10 
μm for all sections and the area of the calibration spot was calculated using the number of pixels 
within a calibration spot with spatial resolution used in the experiment. Concentrations within the 
calibration spots ranged from 1146.8 μM to 2.4 μM. Signal to noise (S/N) for the lowest 
concentration spot was determined to be on average 7.2 and 6.7 for SN-38 and Irinotecan 
respectively, thus lying below the limit of quantification at S/N=10. For several pixels of the lowest 
concentration spot S/N fell below 3, indicating the signal was below the limit of detection. 
 
3. Results & Discussion 
Design and synthesis of SN-38 linkers and dendrimer conjugation 
After synthesising a dendrimer platform with the desired size, surface-modification, and 
biocompatibility [34], we then developed SN-38 linkers with a range of release rates to explore 
differential SN-38 profiles over time. Three linker chemistries were utilised to tune the release rate: 
a primary amine carbamate, an ester, and a secondary amine carbamate, respectively (Scheme 1). 
To generate fast and medium release linkers, the primary amine carbamate and ester linkers were 
synthesised to have sufficient distance from the amide of the linker itself (carbamate) or from the 
amide of the dendrimer coupling (carbamate and ester) to avoid anchimeric assistance to hydrolytic 
breakdown. This effect has been shown to have a significant impact on release rates [45], and was 
exploited to increase release rate. Inclusion of a triazole in the linker design as demonstrated here 
would be expected to reduce this effect by extending and rigidifying the linker such that any 
transition state involving anchimeric assistance would be highly strained and energetically 
disfavoured. To generate a fast release linker, the 1° amine carbamate was used for its increased 
susceptibility to chemical hydrolysis, which we hypothesise is due to a mechanism involving the 
formation of an intermediate isocyanate. This isocyanate decomposes rapidly in the presence of 
water to give a primary amine and carbon dioxide by-product. Hence, to produce a slow release 
linker, we investigated the N-methylated 2° amine carbamate, which cannot undergo this type of 
release mechanism. Consistent with our hypothesis, this linker exhibited a slower release rate. This 
exemplifies how the dendrimer platform can be coupled with unique linker chemistries to achieve 
different release rates to provide desired drug profiles. 
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Scheme 1. Synthesis routes for linker-SN38 compounds 1a-c. (a) ACN/THF, DMAP, RT. (b) DMF, 
EDC/DMAP RT, (c + d) DCM, DIPEA, DMAP (e) DMF, sodium ascorbate, copper II sulphate, RT. 
 
Initially, linkers 1a-c were designed with alkyne groups to conjugate to an azide-modified dendrimer 
through click chemistry. The methodology for the dendrimer synthesis and linker-SN38 conjugation 
is outlined in Scheme 2. At a later stage, an alternative route of synthesis was made for linker 1b 
(linker 1b’) to avoid the use of copper click chemistry in the presence of the polyoxazoline-modified 
dendrimer. Polyoxazoline has been reported to have an affinity for copper in click reactions [46] 
which, although not observed here, was still avoidable by carrying out the purification on the linker 
before conjugating to the dendrimer.  
 
 
 
G5 L-lysine 
dendrimer
=
=
Copper
“Click”
1a-c
1b’
Amide
coupling
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Scheme 2.  Synthetic route to polyoxazoline-modified dendrimers with linker-SN38 conjugation. 
 
 
The drug loading was consistent by employing click chemistry to conjugate SN-38 linkers 1a-c to the 
dendrimer (Table 1). Unreacted SN-38 linker was efficiently removed from the conjugate using a LH-
20 sephadex size exclusion column with methanol eluent; unreacted linker was not detectable by 
HPLC-UV (LoD ~ 0.1 μg/mL). Presumably, the unbound SN-38 detected in sample 2a arose from the 
release of some of the drug during the evaporation and solvent changeover process, since this 
conjugate had the fastest release rate. The unbound SN-38 in 2b’ was a small amount of residual 
drug leftover from the purification process.  
 
Conjugate 2b’ was synthesised differently: the linker was conjugated to the dendrimer through an 
amide coupling step and was purified by ultrafiltration afterwards. This was the most efficient 
method for the preparation of the conjugate since it removed an ultrafiltration purification step 
from the dendrimer after the azide modification and was found to be a better method for larger 
quantities of material. All of the dendrimer conjugates had ca. 8 wt.% of SN-38, which equates to 25 
drug molecules per dendrimer on average. Residual functional groups were not quantified but are 
expected to be minimal given the excess of drug-linker used and the consistencies in the loadings. 
The solubility of the conjugates remained very good but reduced in comparison to the native 
dendrimer. The structural representation of each dendrimer-SN38 conjugate (Dend-SN38) can be 
found in Supporting Information Scheme S1. A representative GPC chromatogram and DLS spectra 
have also been included for conjugate 2b’ in the Supporting Information Fig. S1. 
 
 
Table 1. SN-38 loading and non-conjugated (free) SN-38 for the different dendrimer conjugates. 
 
ND = Not detected (by HPLC-UV). ¥ Conjugated by click chemistry. Ϯ Conjugated through amide coupling. 
 
Dend-SN38 release rates 
The release rates for SN-38 from the Dend-SN38 conjugates were measured in PBS, and 
subsequently in plasma to mimic the in vivo situation more closely. The release rates measured for 
the Dend-SN38 conjugates 2a-c in plasma (Fig. 1B) in vitro were found to differ from those measured 
in PBS (Fig. 1A), presumably due to enzymatically mediated processes, despite the presence of the 
polyoxazoline on the surface of the dendrimer. The range of in vitro plasma release half-lives for the 
three Dend-SN38 conjugates was determined to be 2.5 h (“fast release”), 21 h (“medium release”), 
and 72 h (“slow release”) (Fig. 1B). Based on the drug loading and a 21 h release rate, it was 
predicted that the medium release Dend-SN38 would achieve the desired sustained exposure to 
therapeutic concentrations of SN-38. The fast and slow release linkers were designed to give greater 
insight into the relationship between efficacy and toxicity by providing exposure profiles outside of 
the target plasma level. 
 
Plasma SN-38 pharmacokinetics studies were performed in mice to confirm whether there would be 
a prolonged, therapeutic level of SN-38 in the circulation in vivo (Fig. 1C). The plasma half-life of SN-
38 (carboxylate form) itself in vivo is less than 0.5 h (Supporting Information Fig. S2) and previous 
Dendrimer description Release 
description 
Conjugated SN-38 
wt.% 
Free SN-38 in 
sample wt.% 
2a (1° amine carbamate) Fast 8.1 0.2 
2b (Ester)¥ Medium 8.3 ND 
2b’ (Ester)Ϯ Medium 7.7 0.17 
2c (2° amine carbamate) Slow 8.5 ND 
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reports have shown that the SN-38 generated after administration of irinotecan is rapidly cleared 
[47, 48]. Of the three Dend-SN38 conjugates we designed, only the medium release conjugate 
achieved the desired sustained exposure of SN-38 in vivo. Therapeutic concentrations of SN-38 were 
measured up to 96 h after the administration of this conjugate. As expected for the fast release 
conjugate, the plasma levels of SN-38 quickly diminished within 10-20 h after administration. This is 
consistent with the rapid release of SN-38 from the conjugate (t1/2 =2.5 h) and subsequent rapid 
clearance of liberated SN-38. The slow release conjugate was designed to provide a low but 
consistent exposure to SN-38. However, a short burst release was observed, followed by an 
equilibrated concentration of SN-38, which was below the limit of detection of the instrument 
(UPLC-MS/MS LoD = 5 nM). Given that there was no free drug detected in the sample by HPLC-UV, 
the rationale for the early burst may have originated from some enzymatic action on the more easily 
accessible linkers, since enzymatic cleavage of secondary amine carbamates is known [49]. It is also 
possible that demethylation of enzyme-accessible carbamate groups could have occurred and would 
also have led to faster release of SN-38. Some ex vivo release during sample storage and preparation 
may have been a minor contributing factor. Interestingly, the total SN-38 plasma profile (i.e. 
conjugated plus free SN-38) showed that the slow release conjugate was being cleared faster than 
the medium release conjugate, despite the slower release rate. This is thought to be driven by the 
residual functional groups exposed by the linkers after drug release, i.e. a carboxyl group for the 
ester (medium release) versus a 2o amine for the carbamate (slow release), which could be 
recognised by the mononuclear phagocyte system and cleared from circulation at different 
rates.[50]  
 
 
 
Figure 1. (A) In vitro release of SN-38 in PBS. (B) In vitro plasma release (Wistar rat). (C) In vivo 
pharmacokinetics of SN-38 liberated from the Dend-SN38 conjugates (2a-c). (D) In vivo 
pharmacokinetics for total SN-38 (liberated + conjugated). 
 
In vivo efficacy and safety 
14 
 
The relative anti-tumour efficacy of the Dend-SN38 conjugates at 4 mg/kg versus irinotecan was 
determined using mice bearing subcutaneous SW620 colorectal xenografted tumours. This model 
was selected for its well-characterised response to irinotecan. Dend-SN38 conjugates were 
administered weekly intravenously, at doses expected to achieve therapeutic concentrations of SN-
38 for different periods of time, based on in vitro and in vivo release and pharmacokinetic studies. By 
mass, irinotecan is ~67% SN-38. Irinotecan was dosed at the maximum tolerated i.v. and i.p. doses to 
test two different profiles of plasma exposure and local drug concentration, with the SN-38 
concentrations related proportionally. Intravenous administration achieves a high initial 
concentration, followed by rapid clearance; intraperitoneally dosed irinotecan reaches the plasma 
more slowly and achieves more prolonged drug exposure with a lower Cmax. This more closely mimics 
the clinical standard-of-care of irinotecan infusion.  
 
The SW620 xenograft model has a well characterised, but modest, response to irinotecan. Both i.p. 
and i.v. irinotecan treatment caused a slight reduction in tumour growth (50% inhibition, P<0.01 and 
19% inhibition, P>0.05, respectively), but the tumours continued to progress (Fig. 2A). Changes in 
the growth rate of i.p. irinotecan-treated tumours were observed by day 3 post-dose, whilst little 
response was observed for the i.v. treatment. This supports the value of more prolonged input of 
drug into plasma following i.p. dosing. In contrast to the modest anti-tumour effect of irinotecan, 
treatment with the medium release Dend-SN38 led to significant tumour regression (P<0.001; Fig. 
2A). The deviation from saline controls occurred on day 5 post-dose (versus day 3 post-dose for 
irinotecan) and tumour regression was evident by the third cycle of dosing. At the end of study, 
medium Dend-SN38 treatment had caused 69% tumour regression, while regression was not 
observed with irinotecan treatment. Highlighting the relationship between drug exposure profile 
and anti-tumour efficacy, the fast and slow release conjugates gave no anti-tumour effect (Fig. 2A). 
This is consistent with the low plasma concentrations of released SN-38 seen in the in vivo 
pharmacokinetic evaluation (Fig. 1C). The sustained therapeutic concentration of SN-38 delivered by 
the medium release conjugate resulted in more than a 3-fold reduction in average tumour volume at 
the end of the study. It will be important to test the robustness of the Dend-SN38 conjugate across a 
panel of pre-clinical models to develop greater insight into its clinical potential. 
 
  
 
Figure 2. Efficacy and gastrointestinal toxicity of Dend-SN38 conjugates (2a-c) versus irinotecan 
both i.p. and i.v. at the maximum tolerated dose. (A) Mouse SW620 anti-tumour efficacy plot 
dosing q7d. (B) Mean group bodyweight change during efficacy study. (C) Gastrointestinal toxicity 
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score for crypt atrophy; 0 = no change, 5 = severe changes. (D) Representative gastrointestinal 
tract cross sections of crypt epithelium at 24 h post-last dose; (i) Control, (ii) Irinotecan i.v., (iii) 
Irinotecan i.p., (iv) Medium release Dend-SN38. ** and *** = P< 0.01 and P<0.001 versus Saline at 
Day 16, respectively.  
 
Pre-clinically and clinically, treatment with irinotecan can be limited by certain toxicities, including 
gastrointestinal toxicity [51]. Gastrointestinal toxicity resulting from irinotecan treatment is thought 
to be driven by a number of mechanisms, including direct conversion of irinotecan into SN-38 in the 
intestines, and enzymatic cleavage of the metabolite SN-38G (SN-38 glucuronide) back into SN-38 
during enterohepatic circulation and reabsorption of the drug [52]. These toxicities can be observed 
pathologically in mice. To investigate the effect of repeated doses of the different treatments on the 
gastrointestinal tract, the toxicity was assessed at the end of the study. A pathologist-based 
assessment of H&E-stained samples of the gastrointestinal tract was performed (see Fig. 2D for 
representative images). Baseline toxicity profiles were established using i.v. and i.p. irinotecan 
treatments as positive controls. Irinotecan treatment resulted in minimal to mild degenerative 
effects within the small intestinal crypt epithelium, with generally more severe concomitant atrophic 
changes with i.p. irinotecan treatment (Fig. 2C). This most likely reflects the greater local 
gastrointestinal exposure [53] and extended plasma exposure [54] to irinotecan/SN-38 with the i.p. 
dosing. The pathological analysis of crypt degeneration correlates with mean mouse bodyweight loss 
for the different treatment groups: irinotecan i.p. caused the greatest bodyweight loss, with smaller 
weight fluctuations observed for irinotecan i.v. and medium release dendrimer conjugate, and good 
tolerability for other treatments (Fig. 2B).  
 
The toxicity of the dendrimer conjugates was compared directly to the baseline irinotecan toxicity 
profiles. Each conjugate presented a unique profile of toxicity. While the slow release dendrimer 
conjugate had no impact on the gastrointestinal tract, it also did not exert any therapeutic effect. 
The findings suggest that the concentration of SN-38 in the tumour was too low to provide efficacy. 
Similarly, the fast release dendrimer conjugate showed no anti-tumour activity. However, this is 
thought to be due to the rapid release of the drug and subsequent rapid clearance of the free drug,  
therefore, not providing a prolonged exposure of the drug required in the tumour for efficacy. 
Moreover, this conjugate caused minimal to mild toxicity throughout the small intestine (similar to 
i.v. irinotecan treatment), which is thought to be due to higher initial plasma concentrations 
resulting from more rapid drug release. This suggests that the plasma drug exposure is critical to 
managing the toxicity of irinotecan/SN-38. In contrast, the significantly improved efficacy of the 
medium release Dend-SN38 conjugate was accompanied by reduced gastrointestinal effects relative 
to both irinotecan groups and the fast release Dend-SN38. No atrophic effects were observed in the 
ileum or duodenum, though a small number of animals showed minimal to mild crypt atrophy in the 
jejunum after treatment with the medium release dendrimer conjugate. These observations are 
consistent with a reduction in the plasma Cmax of SN-38 when administered as a polymer therapeutic 
with a prolonged release rate, thus a reduced distribution to the liver and intestines leading to lower 
toxicity.  
 
The combination of potent tumour regression and good gastrointestinal tolerability with the 
medium release dendrimer conjugate is a significant improvement in the therapeutic index of SN-38. 
The superiority of the efficacy of the medium release Dend-SN38 over the slow and fast release 
conjugates made it the logical formulation to investigate further. Additional studies were completed 
to explore the efficacy and pharmacodynamic effects of the medium release conjugate. Henceforth 
the medium release Dend-SN38 conjugate will be referred to as DEND-38. 
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Figure 3. (A) Dose-dependent efficacy for DEND-38 and 72 day re-growth period following final 
dose. (B) Picture of tumours excised at 24 h post-last dose (day 23) representing treatment with (i) 
saline, (ii) irinotecan i.p., (iii) DEND-38 2 mg/kg, (iv) DEND-38 4 mg/kg, and (v) DEND-38 8 mg/kg. 
(C) Schedule-dependent efficacy for weekly versus fortnightly administration of DEND-38 at 4 and 
8 mg/kg. (D) Individual mouse bodyweights during study dosing period. ** and *** = P<0.01 and 
P<0.001 versus Saline at Day 23, respectively; & = 1 mouse without visible tumour at end of study. 
 
The dose-response of DEND-38 was explored in SW620 tumour-bearing mice. As observed above, 
treatment with the standard-of-care irinotecan slowed tumour growth (P<0.01; Fig. 3A-C). In 
contrast, 2, 4 and 8 mg/kg DEND-38 produced tumour regression after two treatments (Fig. 3A-C). 
After four treatments of DEND-38, the majority of tumours at each dose had regressed to less than 
0.05 cm3 (P<0.001).  Both the 4 and 8 mg/kg DEND-38 dose levels produced the same rate of tumour 
regression in this model. The significant tumour regression observed at these doses did not 
necessitate further dose escalation in this model, thus, the maximum tolerated dose was not 
established. All three dose levels of DEND-38 treatment were well tolerated (Fig. 3D). Individual 
animal bodyweights are presented in Supporting Information Fig. S3. The broad therapeutic index of 
DEND-38 provides the opportunity to utilise doses above 8 mg/kg in other less sensitive models to 
achieve efficacy. 
 
The tumour regression achieved in both the 4 and 8 mg/kg treatment groups (peaking at 98% at day 
55 and 96% at day 48, respectively) was maintained for ~7-8 weeks after dosing cessation. After this 
point, slow re-growth was observed. The anti-tumour response and re-growth for all individual 
animals is presented in Supporting Information Fig. S4. At 10 weeks after the final dose, 1/6 mice 
from both groups still showed no evidence of visible tumour. Treatment with 2 mg/kg DEND-38 
produced a delayed initial tumour regression relative to the 4 and 8 mg/kg doses. Moreover, tumour 
re-growth was significantly more rapid at the lowest dose level (peaking at 82% at day 34), showing 
a dose-response effect. While 2 mg/kg DEND-38 represents a low effective dose, future studies will 
investigate tumour control at lower doses. 
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The effect of weekly (every 7 days) and fortnightly (every 14 days) dosing schedules was compared 
to explore the importance of increased AUC versus duration of exposure in driving anti-tumour 
efficacy. Substantially poorer activity was observed with the fortnightly schedule of DEND-38 at both 
4 and 8 mg/kg (Fig. 3C). Over 14 days, two doses of 4 mg/kg achieved tumour regression, while a 
single dose of 8 mg/kg achieved tumour control until day 8-10, and tumour growth resumed by day 
14 post-dose. These data suggest that weekly administrations are required and sufficient to maintain 
therapeutic SN-38 concentrations in tumour. Fortnightly administration demonstrated dose-
dependent anti-tumour efficacy, with 8 mg/kg treatment being superior to 4 mg/kg (P<0.001 vs. 
P<0.01, respectively; Fig. 3C). This is supported by data showing that plasma SN-38 concentrations 
increased with dose (Fig. 3D). A re-challenge of the tumours at day 15 caused a moderate reduction 
in tumour size (Fig. 3C).  
 
The data show that drug release rate influences both efficacy and toxicity. The flexibility in the 
design of the linker provides the opportunity to further optimise the release rate and dosing 
schedule to maximise the therapeutic window. Future pre-clinical work in different tumour types 
and in combination with other agents will seek to understand the drivers of activity, response to re-
challenge, and therapeutic potential with other therapies. Patient tumours typically present with a 
more complex tumour microenvironment than do standard pre-clinical xenograft models. As with all 
novel nanomedicine technologies optimised pre-clinically, it will be important to determine whether 
the efficacy observed in the SW620 model translates to other more patient-relevant models and 
across different genetic backgrounds [18]. 
 
 
            
Figure 4. Tumour pharmacokinetics and pharmacodynamic effects of irinotecan and DEND-38 
treatment. (A) SN-38 concentration in tumours at 24, 72, and 120 h post-dose. (B) DNA damage 
staining for γH2A.X-positive nuclei in tumours at 24, 72, and 120 h post-dose of irinotecan or 
DEND-38. P>0.05 between treatments at each time point. (C) Representative images of γH2A.X 
staining in tumours at 24 h post-dose. (D) DESI-MS detection of SN-38 in tumour sections at 24 h 
post-dose of irinotecan i.p. at 50 mg/kg or DEND-38 i.v. at 4 mg/kg. H&E-stained tumour sections 
shown in Supporting Information Fig. S5. 
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To investigate the time course of drug accumulation and DNA damage following exposure to 
irinotecan/SN-38, tumour pharmacokinetics and pharmacodynamic effect were analysed up to 5 
days post-dose. Tumours were harvested and divided in half for IHC analysis of DNA damage or MS 
imaging of drug distribution and subsequent SN-38 quantification. Quantification of SN-38 in tumour 
homogenates revealed that treatment with DEND-38 achieved ~10-fold greater accumulation of SN-
38 in tumours than did treatment with irinotecan (Fig. 4A). This was observed at all three time points 
tested. DEND-38 treatment maintains sustained levels of SN-38 in tumours for at least 120 h post-
dose. In contrast, in the irinotecan-treated group, SN-38 concentrations dropped below the target 
concentration by 72 h post-dose, and were no longer detectable at 120 h (Fig. 4A).  
 
Treatment with a single dose of either DEND-38 or the clinical standard-of-care irinotecan causes 
sustained DNA damage in tumours (Fig. 4B,C), but does not affect cell proliferation in tumours (as 
determined by Ki67 staining; data not shown). After a single dose, DNA damage can be observed at 
24 h and persists for at least 5 days. This implies that the DNA damage triggered by irinotecan 
persists for several days after the drug is cleared from the tumour. This study demonstrates proof of 
mechanism of action of the anti-tumour effect of DEND-38, attributed to the accumulation of drug in 
the tumour (see below). While there is not a significant difference in the level of DNA damage after 
the initial dose of irinotecan or DEND-38 (P>0.05), there is also little differentiation in the tumour 
growth curves for the irinotecan and DEND-38 treatment groups after a single dose. Future studies 
will be required to investigate DNA damage after repeated cycles of dosing and will strive to 
elucidate the biological effects beyond DNA damage that underpin the differential efficacy achieved 
by DEND-38 and irinotecan treatment. 
 
To build on tumour pharmacokinetic analyses and provide insight into the cellular level distribution 
of drug throughout the tumour, mass spectrometry imaging was employed to characterise the 
distribution of SN-38 and irinotecan in tumour slices at 24 h post-dose. In the DEND-38-treated 
tumours, SN-38 was detectable in all four tumours analysed (Fig. 4D). Drug was localised peripherally 
and in focalised regions in the core of the tumours. In the SW620 model, the core is often a region of 
lower cellularity, necrosis, or increased fluid, which may allow for enhanced distribution and could 
serve as a drug depot. SN-38 was not detectable at 72 h or 120 h after the DEND-38 dose (Fig. 4D), 
as it had fallen below the limit of detection (approximately 200 nM; see Supporting Information Fig. 
S6). This is in agreement with concentration data derived using LC-MS showing SN-38 concentrations 
to be below 100 nm at 72 h and 120 h. In irinotecan-treated tumours, both free SN-38 and 
irinotecan were below the limit of detection in all three tumours tested at 24 h (Fig. 4D). These data 
present the drug distribution in a single, central tumour slice. Although not the focus of this article, it 
will be important to build more detailed insight into the distribution of the drug using a series of 
tumour slices and a panel of tumour models. 
 
 
4. Conclusions 
We have shown proof-of-principle that a novel dendrimer technology with SN-38, the active 
metabolite from irinotecan, conjugated through a linker can be used in the treatment of SW620 
human colon cancer xenografts. Tuning the release rate of SN-38 from the dendrimer conjugates 
made it possible to explore a range of drug exposure profiles. While the present study focused on 
generating conjugates with three distinct drug release profiles in mouse plasma, for evaluation of 
the panel in pre-clinical mouse studies, future work will be required to fine-tune the system to 
achieve appropriate release rates in various species, including humans, to translate this system to 
the clinic. The medium release dendrimer-SN38 conjugate with a half life of 21 h achieved sustained 
therapeutic concentrations of SN-38 in plasma and tumour compared with irinotecan. We evaluated 
the dose-response for two different schedules to investigate the impact of dose and regimen on the 
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efficacy of the medium release dendrimer conjugate. We found that a dose of 4 mg/kg together with 
a weekly dosing schedule gave substantial tumour response and led to survival of the treated mice 
72 days following the final dose. The use of DESI-MS in addition to UPLC-MS and DNA damage 
staining elucidated that whilst irinotecan caused DNA damage to large numbers of the tumour cells, 
sustained exposure to SN-38 over an extended period was required to attain the desired tumour 
regression. Finally, we have developed a nanomedicine system that can deliver a dramatically 
improved therapeutic index for SN-38, with both substantially increased efficacy and reduced 
toxicity versus the prodrug irinotecan.  
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